Share & volunteer toolkit

Spread the campaign in a few clicks. Everything below is written to be calm, accurate, and public-health focused — please keep it that way.

Campaign link

Share on…

X / Twitter Facebook Reddit Email Text

Links open with a pre-written, editable message.

Ready-to-copy messages

Short message

DEA may emergency-schedule SR-17018 before its opioid-withdrawal potential can be properly studied. Ask Congress, DEA, and FDA to preserve research access and require compound-specific review.

X / Twitter

DEA may emergency-schedule SR-17018 before it can be studied for opioid-withdrawal potential. Ask Congress, DEA & FDA to preserve research access and require compound-specific review.

Facebook

DEA has named SR-17018 in a temporary scheduling notice. Many people report it may have helped them stop opioids with reduced withdrawal. This isn't a call for unregulated sales — it's a call to study the compound and preserve lawful research access before Schedule I.

Text message

DEA may emergency-schedule SR-17018 before it can be studied. Takes 2 min to ask Congress/DEA/FDA to preserve research access: https://example.org/

Reddit — short post

DEA may emergency-schedule SR-17018 / 5,6-dichloro desmethylchlorphine before its opioid-withdrawal potential can be properly studied. Ask Congress, DEA, and FDA to preserve research access and require compound-specific review. Not a call for unregulated sales or sourcing.

Reddit — longer post

DEA has named SR-17018 / 5,6-dichloro desmethylchlorphine in a temporary scheduling notice. Many people report that SR-17018 may have helped them stop opioids with reduced withdrawal, but emergency Schedule I placement could make legitimate research much harder. This campaign is not asking for unregulated sales or giving sourcing/dosing info. It is asking DEA, FDA/HHS, and Congress to preserve research access, require compound-specific review, and avoid blocking a potentially important opioid-withdrawal research path before it can be studied.

Email to friends

I'm sharing this because DEA may emergency-schedule SR-17018 before its potential opioid-withdrawal applications can be properly studied. The campaign is asking for compound-specific review, published evidence, and preservation of lawful research access. It only takes a few minutes to generate a letter, email, or call script for Congress and relevant agencies.

Flyer text

STUDY IT BEFORE YOU SCHEDULE IT

DEA has announced intent to place SR-17018 into Schedule I. People report it may help reduce opioid withdrawal. These reports are not clinical proof — but they are strong enough to justify urgent research and compound-specific review, not emergency prohibition.

Ask Congress, DEA, and FDA/HHS to:
  • Delay or narrow emergency scheduling of SR-17018 specifically
  • Separate it from other compounds
  • Publish compound-specific evidence
  • Preserve lawful research access

Send a letter, email, or call script in a few minutes: https://example.org/

Responsible advocacy

Do not share vendor names.
Do not share dosing instructions.
Do not encourage stockpiling.
Do not make absolute medical claims.

Do focus on research access, public health, and compound-specific review.